PUF Ventures Launches Cannabidiol Product Line

medicalmarijuana July 11, 2017 Comments Off on PUF Ventures Launches Cannabidiol Product Line
PUF Ventures Launches Cannabidiol Product Line

PUF Ventures Inc., an advanced Access to Cannabis for Medical Purposes Regulations license applicant, is pleased to announce the launch of its nutraceutical cannabidiol (“CBD”) product line. Manufactured in the United States under stringent quality control adherence and derived from high quality industrial hemp, PUF aims to initially focus the distribution of the products in Canada and in Europe with a specific emphasis on Germany and Croatia. The Company will introduce the new CBD line to physicians and naturopathic practitioners in Europe. Initial product-testing phase in the German marketplace is expected to commence in the near future at which time PUF will unveil its CBD brand.

“The CBD market is rapidly expanding as both the medical community and retail consumers alike are beginning to awaken to the potential nutraceutical benefits of cannabidiol,” stated Mr. Derek Ivany, PUF President and CEO. “The addition of our own CBD product line diversifies our future product portfolio and provides a toe-hold into this exciting and potentially lucrative segment of the cannabis industry. Europe represents a significant opportunity for our Company.”

CBD is a natural compound found throughout the seeds, stalk and flowers of cannabis plants including marijuana and hemp. It is a cannabinoid that occurs naturally in significant quantities in cannabis, and has shown to be non-psychoactive or less psychoactive than THC-dominant strains make it an appealing option for medical patients. Scientific and clinical research is on going but early indications show that CBD is a potential treatment for patients looking for relief from  inflammation,  pain,  anxiety,  psychosisseizures, spasms, and other conditions.

Hemp and hemp derived CBD products are among the fastest growing segments in the cannabis industry.  A recent article published in The Hemp Business Journal indicated an expected CBD consumer market of $2.1 billion by 2020, which represents a 700% growth rate in CBD sales from current levels.

Comments are closed.